Schrodinger Inc
NASDAQ:SDGR

Watchlist Manager
Schrodinger Inc Logo
Schrodinger Inc
NASDAQ:SDGR
Watchlist
Price: 19.73 USD -0.15% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Schrodinger Inc?
Write Note

Schrodinger Inc
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Schrodinger Inc
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Schrodinger Inc
NASDAQ:SDGR
Other Current Liabilities
$41.8m
CAGR 3-Years
-2%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Veeva Systems Inc
NYSE:VEEV
Other Current Liabilities
$750.5m
CAGR 3-Years
20%
CAGR 5-Years
24%
CAGR 10-Years
24%
Inspire Medical Systems Inc
NYSE:INSP
Other Current Liabilities
$1.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Other Current Liabilities
$119.1m
CAGR 3-Years
13%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Other Current Liabilities
$164.2m
CAGR 3-Years
10%
CAGR 5-Years
11%
CAGR 10-Years
10%
W
Waystar Holding Corp
NASDAQ:WAY
Other Current Liabilities
$30m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Schrodinger Inc
Glance View

Market Cap
1.4B USD
Industry
Health Care

In the bustling realm of computational chemistry, Schrödinger Inc. has carved a unique niche, transforming the way pharmaceutical and biotechnology companies approach drug discovery. Founded in 1990, the company has become synonymous with innovation, leveraging powerful physics-based software platforms that simulate molecular interactions at an atomic level. By providing researchers with tools to predict the behavior of complex biological systems, Schrödinger effectively bridges the gap between traditional experimental methods and cutting-edge computational techniques. Their flagship product, the Schrödinger platform, is instrumental in accelerating the drug discovery process, allowing scientists to virtually test countless compounds before selecting the most promising candidates for laboratory synthesis and testing. This capability significantly reduces the time and cost involved in bringing new drugs to market, providing tremendous value to its clients in the pharmaceutical industry. Schrödinger's financial success stems from its diversified business model, which includes software licensing, collaborative research and development projects, and, interestingly, strategic investments in biotech firms. The company licenses its software to a broad range of industries, from pharmaceuticals to materials science, generating a steady stream of revenue. Meanwhile, their collaborative projects enable Schrödinger to participate in revenue sharing or milestone payments based on the compounds developed using their technology. Additionally, by investing in biotech companies utilizing their software, Schrödinger not only fosters innovation but also stands to gain financially from any commercial success. This multifaceted approach not only secures their leadership in the industry but also ensures a robust growth trajectory, as they continue to expand the horizons of computational science.

SDGR Intrinsic Value
15 USD
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Schrodinger Inc's Other Current Liabilities?
Other Current Liabilities
41.8m USD

Based on the financial report for Sep 30, 2024, Schrodinger Inc's Other Current Liabilities amounts to 41.8m USD.

What is Schrodinger Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
20%

Over the last year, the Other Current Liabilities growth was -6%. The average annual Other Current Liabilities growth rates for Schrodinger Inc have been -2% over the past three years , 20% over the past five years .

Back to Top